# PlaqueTec's BIOPATTERN Trial Recruits 100th Patient and Expands to Eight NHS Cardiac Centers > PlaqueTec's BIOPATTERN trial has recruited its 100th patient and expanded to eight NHS cardiac centers. - Published: 2026-11-13T05:59:53+00:00 - Section: Research & Clinical Trials - Author: News Desk - URL: https://newsforagent.com/news/2026-11-13/plaquetec-biopattern-trial-100-patients - Source: [News-Medical](https://www.news-medical.net/news/20261112/PlaqueTece28099s-BIOPATTERN-trial-passes-100-patients-and-expands-to-8-NHS-centers.aspx) ## Key takeaways - PlaqueTec's BIOPATTERN trial has recruited its 100th patient and expanded to eight NHS specialist cardiac centers. - St Bartholomew's Hospital in London and Leeds General Infirmary are now recruiting, with Blackpool Victoria and Queen Elizabeth Birmingham set up and ready to start. - Recruitment toward the trial's 300-patient target is expected to complete in 2027. PlaqueTec's BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist cardiac centers, the company announced. [News-Medical](https://www.news-medical.net/news/20261112/PlaqueTece28099s-BIOPATTERN-trial-passes-100-patients-and-expands-to-8-NHS-centers.aspx) reported the milestone on November 13, 2026. Recruitment toward the trial's 300-patient target is expected to complete in 2027. ## PlaqueTec Adds St Bartholomew's and Leeds General Infirmary [PlaqueTec](https://akta.pro/company-profiles/0003wor/plaquetec) is a UK clinical-stage medtech company developing an intracoronary catheter, the Liquid Biopsy System, and the BioCarta data repository to endotype coronary artery disease. St Bartholomew's Hospital in London and [Leeds](https://akta.pro/company-profiles/003cc86/leeds-teaching-hospitals) General Infirmary are now recruiting, while Blackpool Victoria and Queen Elizabeth Birmingham are set up and ready to start. The new sites join Royal Papworth Hospital in Cambridge, Norfolk and Norwich University Hospital, Royal Bournemouth Hospital and the Bristol Heart Institute, extending the network across England. BIOPATTERN aims to uncover the patient-specific mechanisms driving coronary artery disease and identify novel drug targets for personalized medicines. The trial uses the Liquid Biopsy System to sample blood directly at the site of coronary plaque, measuring thousands of biomolecules where the disease is active. These data feed BioCarta, which the company says will help define patient sub-groups and new therapeutic targets for patient stratification and drug development. The trial is run by Papworth Trials Unit Collaboration with PlaqueTec and overseen by a Trial Steering Committee chaired by Professor Peter Libby of Harvard Medical School. Dr. Stephen Hoole, Consultant Cardiologist at Royal Papworth Hospital and BIOPATTERN trial Chief Investigator, said: "One-size-fits-all treatment for coronary disease leaves many patients carrying significant residual risk." Dr. Simon Williams, General Manager of PlaqueTec, said passing 100 participants and growing to eight NHS centers is important progress. ## PlaqueTec's Funding and BioCarta Records According to akta.pro [company records](https://akta.pro/company-data), PlaqueTec closed an oversubscribed $5 million financing in April 2026, funded entirely by existing shareholders, to expand BioCarta. A separate £3.7 million oversubscribed round in May 2026 was advised by Burges Salmon. The same records list total funding of $18 million and three funding rounds on file, including an $8 million round in April 2024 used to support BIOPATTERN and build the BioCarta database. A pre-specified interim analysis in May 2025 reviewed samples from 33 of the first 34 patients enrolled. ## Heart Drug Setbacks Elsewhere in Cardiology Merck KGaA will drop an experimental heart drug it acquired from Silence Therapeutics, citing the failure of a similar treatment by Novartis, [Bloomberg](https://www.bloomberg.com/news/articles/2026-11-12/merck-kgaa-drops-heart-drug-as-novartis-trial-flop-sows-doubts) reported on November 12, 2026. Vasa Therapeutics announced positive topline results from a randomized, placebo-controlled Phase 1c trial of VS-041 for heart failure with preserved ejection fraction, showing a reduction in NT-proBNP after 28 days, [PR Newswire](https://www.prnewswire.com/news-releases/vasa-therapeutics-announces-positive-topline-results-from-randomized-placebo-controlled-phase-1c-trial-of-vs-041-for-treatment-of-heart-failure-with-preserved-ejection-fraction-hfpef-302936860.html) reported the same day. ## Vasa's 2027 Data and PlaqueTec's Recruitment Target Vasa Therapeutics said ongoing analyses of fibroinflammation markers from its Phase 1c trial will be presented in early 2027, according to PR Newswire. PlaqueTec expects recruitment toward the 300-patient BIOPATTERN target to complete in 2027. ## Companies in this story - [PlaqueTec company profile](https://akta.pro/company-profiles/0003wor/plaquetec) · website: https://www.plaquetec.com - [Leeds Teaching Hospitals company profile](https://akta.pro/company-profiles/003cc86/leeds-teaching-hospitals) · website: http://www.leedsth.nhs.uk --- News for Agent · https://newsforagent.com/llms.txt